Improvement of lipid metabolism with fenofibrate in gynaecological borderline cases.
The effect of fenofibrate (Lipanthyl) on the more important lipid levels has been examined in 58 female patients. The other diseases of the women have been treated as well. The drug moderated cholesterol level very successfully. In response to the drug the serum cholesterol, serum triglyceride and LDL-cholesterol values decreased and the HDL-cholesterol level increased. The long-term application of the drug was well tolerated by the women. The introduction of fenofibrate is recommended in particular in the treatment of those internal-gynaecological diseases and postmenopause in which the normal lipid levels may facilitate to reach the final goal of therapy.
Sásdi
A
A
Second Department of Obstetrics and Gynaecology, Semmelweis University Medical School, Budapest.
D000328:Adult; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D011345:Fenofibrate / Q000494:pharmacology*; D005831:Genital Diseases, Female / Q000150:complications; D006801:Humans; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood*
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides; D002784:Cholesterol; D011345:Fenofibrate